Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial
Background Understanding the patterns of treatment response is critical for the treatment of patients with schizophrenia; one way to achieve this is through using a longitudinal dynamic process study design. Aims This study aims to explore the response trajectory of antipsychotics and compare the t...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2020-11-01
|
| Series: | BJPsych Open |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472420001052/type/journal_article |
| _version_ | 1811157042882150400 |
|---|---|
| author | Minhan Dai Yulu Wu Yiguo Tang Weihua Yue Hao Yan Yamin Zhang Liwen Tan Wei Deng Qi Chen Guigang Yang Tianlan Lu Lifang Wang Fude Yang Fuquan Zhang Jianli Yang Keqing Li Luxian Lv Qingrong Tan Hongyan Zhang Xin Ma Lingjiang Li Chuanyue Wang Xiaohong Ma Dai Zhang Hao Yu Liansheng Zhao Hongyan Ren Yingcheng Wang Xun Hu Guangya Zhang Xiaodong Du Qiang Wang Tao Li |
| author_facet | Minhan Dai Yulu Wu Yiguo Tang Weihua Yue Hao Yan Yamin Zhang Liwen Tan Wei Deng Qi Chen Guigang Yang Tianlan Lu Lifang Wang Fude Yang Fuquan Zhang Jianli Yang Keqing Li Luxian Lv Qingrong Tan Hongyan Zhang Xin Ma Lingjiang Li Chuanyue Wang Xiaohong Ma Dai Zhang Hao Yu Liansheng Zhao Hongyan Ren Yingcheng Wang Xun Hu Guangya Zhang Xiaodong Du Qiang Wang Tao Li |
| author_sort | Minhan Dai |
| collection | DOAJ |
| description | Background
Understanding the patterns of treatment response is critical for the treatment of patients with schizophrenia; one way to achieve this is through using a longitudinal dynamic process study design.
Aims
This study aims to explore the response trajectory of antipsychotics and compare the treatment responses of seven different antipsychotics over 6 weeks in patients with schizoprenia (trial registration: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934).
Method
Data were collected from a multicentre, randomised open-label clinical trial. Patients were evaluated with the Positive and Negative Syndrome Scale (PANSS) at baseline and follow-up at weeks 2, 4 and 6. Trajectory groups were classified by the method of k-means cluster modelling for longitudinal data. Trajectory analyses were also employed for the seven antipsychotic groups.
Results
The early treatment response trajectories were classified into a high-trajectory group of better responders and a low-trajectory group of worse responders. The results of trajectory analysis showed differences compared with the classification method characterised by a 50% reduction in PANSS scores at week 6. A total of 349 patients were inconsistently grouped by the two methods, with a significant difference in the composition ratio of treatment response groups using these two methods (χ2 = 43.37, P < 0.001). There was no differential contribution of high- and low trajectories to different drugs (χ2 = 12.52, P = 0.051); olanzapine and risperidone, which had a larger proportion in the >50% reduction at week 6, performed better than aripiprazole, quetiapine, ziprasidone and perphenazine.
Conclusions
The trajectory analysis of treatment response to schizophrenia revealed two distinct trajectories. Comparing the treatment responses to different antipsychotics through longitudinal analysis may offer a new perspective for evaluating antipsychotics.
|
| first_indexed | 2024-04-10T04:59:35Z |
| format | Article |
| id | doaj.art-d3d80979428d4eea9143014ea604dce7 |
| institution | Directory Open Access Journal |
| issn | 2056-4724 |
| language | English |
| last_indexed | 2024-04-10T04:59:35Z |
| publishDate | 2020-11-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | BJPsych Open |
| spelling | doaj.art-d3d80979428d4eea9143014ea604dce72023-03-09T12:29:03ZengCambridge University PressBJPsych Open2056-47242020-11-01610.1192/bjo.2020.105Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trialMinhan Dai0Yulu Wu1Yiguo Tang2Weihua Yue3Hao Yan4Yamin Zhang5https://orcid.org/0000-0002-6515-9106Liwen Tan6Wei Deng7Qi Chen8Guigang Yang9Tianlan Lu10Lifang Wang11Fude Yang12Fuquan Zhang13Jianli Yang14Keqing Li15Luxian Lv16Qingrong Tan17Hongyan Zhang18Xin Ma19Lingjiang Li20Chuanyue Wang21Xiaohong Ma22Dai Zhang23Hao Yu24https://orcid.org/0000-0002-9785-8489Liansheng Zhao25Hongyan Ren26Yingcheng Wang27Xun Hu28Guangya Zhang29Xiaodong Du30Qiang Wang31Tao Li32Mental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaPeking University Sixth Hospital (Institute of Mental Health), China; and National Clinical Research Center for Mental Disorders and Key Laboratory of Mental Health, Ministry of Health (Peking University), ChinaPeking University Sixth Hospital (Institute of Mental Health), China; and National Clinical Research Center for Mental Disorders and Key Laboratory of Mental Health, Ministry of Health (Peking University), ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; West China Brain Research Center, West China Hospital of Sichuan University, ChinaSecond Xiangya Hospital, Central South University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaSecond Xiangya Hospital, Central South University, ChinaBeijing Anding Hospital, Institute for Brain Disorders, Capital Medical University, ChinaPeking University Sixth Hospital (Institute of Mental Health), China; and National Clinical Research Center for Mental Disorders and Key Laboratory of Mental Health, Ministry of Health (Peking University), ChinaPeking University Sixth Hospital (Institute of Mental Health), China; and National Clinical Research Center for Mental Disorders and Key Laboratory of Mental Health, Ministry of Health (Peking University), ChinaBeijing HuiLongGuan Hospital, ChinaWuxi Mental Health Center, Nanjing Medical University, ChinaInstitute of Mental Health, Tianjin Anding Hospital, China; and Tianjin Medical University General Hospital, Tianjin Medical University, ChinaHebei Mental Health Center, ChinaSecond Affiliated Hospital of Xinxiang Medical University, ChinaDepartment of Psychiatry, Xijing Hospital, Fourth Military Medical University, ChinaWuxi Mental Health Center, Nanjing Medical University, ChinaBeijing Anding Hospital, Institute for Brain Disorders, Capital Medical University, ChinaSecond Xiangya Hospital, Central South University, ChinaBeijing Anding Hospital, Institute for Brain Disorders, Capital Medical University, Beijing, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaPeking University Sixth Hospital (Institute of Mental Health), China; and National Clinical Research Center for Mental Disorders and Key Laboratory of Mental Health, Ministry of Health (Peking University), ChinaDepartment of Psychiatry, Jining Medical University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; West China Brain Research Center, West China Hospital of Sichuan University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaWest China Brain Research Center, West China Hospital of Sichuan University, China; and Biobank, West China Hospital of Sichuan University, ChinaSuzhou Psychiatric Hospital, The Affiliated Guangji Hospital of Soochow University, ChinaSuzhou Psychiatric Hospital, The Affiliated Guangji Hospital of Soochow University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaMental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, China; and West China Brain Research Center, West China Hospital of Sichuan University, ChinaBackground Understanding the patterns of treatment response is critical for the treatment of patients with schizophrenia; one way to achieve this is through using a longitudinal dynamic process study design. Aims This study aims to explore the response trajectory of antipsychotics and compare the treatment responses of seven different antipsychotics over 6 weeks in patients with schizoprenia (trial registration: Chinese Clinical Trials Registry Identifier: ChiCTR-TRC-10000934). Method Data were collected from a multicentre, randomised open-label clinical trial. Patients were evaluated with the Positive and Negative Syndrome Scale (PANSS) at baseline and follow-up at weeks 2, 4 and 6. Trajectory groups were classified by the method of k-means cluster modelling for longitudinal data. Trajectory analyses were also employed for the seven antipsychotic groups. Results The early treatment response trajectories were classified into a high-trajectory group of better responders and a low-trajectory group of worse responders. The results of trajectory analysis showed differences compared with the classification method characterised by a 50% reduction in PANSS scores at week 6. A total of 349 patients were inconsistently grouped by the two methods, with a significant difference in the composition ratio of treatment response groups using these two methods (χ2 = 43.37, P < 0.001). There was no differential contribution of high- and low trajectories to different drugs (χ2 = 12.52, P = 0.051); olanzapine and risperidone, which had a larger proportion in the >50% reduction at week 6, performed better than aripiprazole, quetiapine, ziprasidone and perphenazine. Conclusions The trajectory analysis of treatment response to schizophrenia revealed two distinct trajectories. Comparing the treatment responses to different antipsychotics through longitudinal analysis may offer a new perspective for evaluating antipsychotics. https://www.cambridge.org/core/product/identifier/S2056472420001052/type/journal_articleTrajectoriesantipsychotic drugsschizophreniatreatment responseclinical trial |
| spellingShingle | Minhan Dai Yulu Wu Yiguo Tang Weihua Yue Hao Yan Yamin Zhang Liwen Tan Wei Deng Qi Chen Guigang Yang Tianlan Lu Lifang Wang Fude Yang Fuquan Zhang Jianli Yang Keqing Li Luxian Lv Qingrong Tan Hongyan Zhang Xin Ma Lingjiang Li Chuanyue Wang Xiaohong Ma Dai Zhang Hao Yu Liansheng Zhao Hongyan Ren Yingcheng Wang Xun Hu Guangya Zhang Xiaodong Du Qiang Wang Tao Li Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial BJPsych Open Trajectories antipsychotic drugs schizophrenia treatment response clinical trial |
| title | Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial |
| title_full | Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial |
| title_fullStr | Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial |
| title_full_unstemmed | Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial |
| title_short | Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial |
| title_sort | longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia 6 week randomised open label multicentre clinical trial |
| topic | Trajectories antipsychotic drugs schizophrenia treatment response clinical trial |
| url | https://www.cambridge.org/core/product/identifier/S2056472420001052/type/journal_article |
| work_keys_str_mv | AT minhandai longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT yuluwu longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT yiguotang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT weihuayue longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT haoyan longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT yaminzhang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT liwentan longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT weideng longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT qichen longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT guigangyang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT tianlanlu longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT lifangwang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT fudeyang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT fuquanzhang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT jianliyang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT keqingli longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT luxianlv longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT qingrongtan longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT hongyanzhang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT xinma longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT lingjiangli longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT chuanyuewang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT xiaohongma longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT daizhang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT haoyu longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT lianshengzhao longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT hongyanren longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT yingchengwang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT xunhu longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT guangyazhang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT xiaodongdu longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT qiangwang longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial AT taoli longitudinaltrajectoryanalysisofantipsychoticresponseinpatientswithschizophrenia6weekrandomisedopenlabelmulticentreclinicaltrial |